 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
5 News |  |
- | ANX-042 / Anexon
Trial completion date, Trial primary completion date: ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - Mar 8, 2023
P1, N=60, Enrolling by invitation, Sponsor: Mayo Clinic
Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- | ANX-042 / Anexon, cenderitide (CD-NP) / Capricor
Journal: Innovative Therapeutics: Designer Natriuretic Peptides. (Pubmed Central) - May 14, 2017
In this review, we report the conceptual framework of peptide engineering of the natriuretic peptides that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension, which include Cenderitide, ANX042 and ZD100.
- ANX-042 / Anexon
New P1 trial: ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - Jan 12, 2017
P1, N=60, Enrolling by invitation, Sponsor: Mayo Clinic
- | ANX-042 / Anexon
Trial completion: ANX-042 Healthy Volunteer Dose Escalation Study (clinicaltrials.gov) - Jan 3, 2013
P1, N=30, Completed, Sponsor: Anexon, Incorporated
We specifically provide an update on those currently in clinical trials for heart failure and hypertension, which include Cenderitide, ANX042 and ZD100. Recruiting --> Completed
- ANX-042 / Anexon
Enrollment change: ANX-042 Healthy Volunteer Dose Escalation Study (clinicaltrials.gov) - Nov 1, 2012
P1, N=30, Completed, Sponsor: Anexon, Incorporated
Recruiting --> Completed N=18 --> 30
- | ANX-042 / Anexon
New P1 trial: ANX-042 Healthy Volunteer Dose Escalation Study (clinicaltrials.gov) - Jul 9, 2012
P1, N=30, Completed, Sponsor: Anexon, Incorporated